Abstract
This communication provides the justification supporting the selection of the mepolizumab 300 mg subcutaneous (SC) dose in patients with eosinophilic granulomatosis with polyangiitis (EGPA) or hyper-eosinophilic syndrome (HES).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
